FDA Drops REMS Requirements for CAR T Therapies To Expand Access

By Maaisha Osman / June 30, 2025 at 5:15 PM

FDA has removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for six approved autologous CAR T cell therapies, marking a major regulatory shift that could accelerate patient access to these potentially life-saving cancer treatments.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.